NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Phio Pharmaceuticals Corp (NASDAQ: PHIO)

 
PHIO Technical Analysis
5
As on 13th Jan 2025 PHIO STOCK Price closed @ 6.60 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 1.15 & Strong Buy for SHORT-TERM with Stoploss of 2.08 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

PHIOSTOCK Price

Open 4.16 Change Price %
High 9.79 1 Day 4.91 290.53
Low 4.11 1 Week 4.80 266.67
Close 6.60 1 Month 4.09 162.95
Volume 279697752 1 Year 3.83 138.27
52 Week High 6.18 | 52 Week Low 0.55
 
NASDAQ USA Most Active Stocks
AMRS 0.14 100.00%
PHIO 6.60 290.53%
BHAT 0.06 -33.33%
NVDA 133.23 -1.97%
LMDX 0.02 0.00%
SLRX 3.67 135.26%
AKTS 0.04 0.00%
LCID 3.01 -0.33%
PONO 1.72 2.38%
TELL 1.00 0.00%
 
NASDAQ USA Top Gainers Stocks
KTRA 6.30 2763.64%
IDRA 8.64 1909.30%
REDU 3.41 1075.86%
CTXRW 0.14 600.00%
PHIO 6.60 290.53%
WINVW 0.03 200.00%
NDRAW 0.03 200.00%
GDEVW 0.05 150.00%
GLSPT 33.43 138.62%
SLRX 3.67 135.26%
 
NASDAQ USA Top Losers Stocks
OTIC 0.01 -91.67%
PTRAW 0.23 -89.59%
ACAQ-UN 2.50 -73.49%
AGBA 0.35 -71.31%
AXAS 0.03 -70.00%
TFFP 0.06 -62.50%
MILEW 0.06 -53.85%
NVVEW 0.01 -50.00%
NLSPW 0.01 -50.00%
LOTZW 0.01 -50.00%
 
 
PHIO
Daily Charts
PHIO
Intraday Charts
Whats New @
Bazaartrend
PHIO
Free Analysis
 
PHIO Important Levels Intraday
RESISTANCE17.55
RESISTANCE14.04
RESISTANCE11.87
RESISTANCE9.70
SUPPORT3.50
SUPPORT1.33
SUPPORT-0.84
SUPPORT-4.35
 
PHIO Forecast January 2025
4th UP Forecast8.74
3rd UP Forecast8.05
2nd UP Forecast7.63
1st UP Forecast7.2
1st DOWN Forecast6
2nd DOWN Forecast5.57
3rd DOWN Forecast5.15
4th DOWN Forecast4.46
 
PHIO Weekly Forecast
4th UP Forecast7.27
3rd UP Forecast7.06
2nd UP Forecast6.92
1st UP Forecast6.79
1st DOWN Forecast6.41
2nd DOWN Forecast6.28
3rd DOWN Forecast6.14
4th DOWN Forecast5.93
 
PHIO Forecast2025
4th UP Forecast24.5
3rd UP Forecast18.76
2nd UP Forecast15.21
1st UP Forecast11.66
1st DOWN Forecast1.54
2nd DOWN Forecast-2.01
3rd DOWN Forecast-5.56
4th DOWN Forecast-11.3
 
 
PHIO Other Details
Segment EQ
Market Capital 22331760.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
PHIO Address
PHIO
 
PHIO Latest News
 
Your Comments and Response on Phio Pharmaceuticals Corp
 
PHIO Business Profile
Phio Pharmaceuticals Corp., a biotechnology company, develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on silencing tumor-induced suppression of the immune system. The company develops PH-762 which targets the checkpoint protein PD-1 on immune cells for used in adoptive cell transfer (ACT); PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for used in ACT; and PH-790 which targets PD-L1 protein that keeps immune cells from attacking nonharmful cells in the body. It has collaborations with the Gustave Roussy and Medigene AG, as well as with Helmholtz Zentrum München. Phio Pharmaceuticals has collaboration with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts. Address: 257 Simarano Drive, Marlborough, MA, United States, 01752
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service